The Binding Site’s Post

Join Dr. Robert H. Christenson and Dr. Phillip D. Levy as they explore the groundbreaking potential of high sensitivity diagnostic immunoassay testing in our live webinar on Wednesday, September 18th at 1:00 PM ET / 12:00 PM CT / 10:00 AM PT, hosted by Medical Laboratory Observer. Learn more about how these advancements are shaping the future of cardiac care and beyond! Register Today ➡ https://lnkd.in/dWUfyA9r #DiagnosticTesting #Immunoassay #CardiacCare #ClinicalDiagnostics #PrecisionMedicine

Join Dr. Robert H. Christenson and Dr. Phillip D. Levy as they explore the groundbreaking potential of high sensitivity diagnostic immunoassay testing in our live webinar on Wednesday, September 18th at 1:00 PM ET / 12:00 PM CT / 10:00 AM PT, hosted by Medical Laboratory Observer. Learn more about how these advancements are shaping the future of cardiac care and beyond! Register Today ➡ https://lnkd.in/dWUfyA9r #DiagnosticTesting #Immunoassay #CardiacCare #ClinicalDiagnostics #PrecisionMedicine

Join Dr. Robert H. Christenson and Dr. Phillip D. Levy as they explore the groundbreaking potential of high sensitivity diagnostic immunoassay testing in our live webinar on Wednesday, September 18th at 1:00 PM ET / 12:00 PM CT / 10:00 AM PT, hosted by Medical Laboratory Observer. Learn more about how these advancements are shaping the future of cardiac care and beyond! Register Today ➡ https://lnkd.in/dWUfyA9r #DiagnosticTesting #Immunoassay #CardiacCare #ClinicalDiagnostics #PrecisionMedicine

Today, we presented first-time clinical data from the Phase 1 study of trispecific TREAT™ antibody, ISB 2001, showing high overall response rate (ORR), with high response rate and favorable safety profile in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM). Notably, no dose-limited toxicities were observed at weekly subcutaneous doses up to 1.2 mg/kg, with mostly mild Cytokine Release Syndrome, no cases of neurotoxicity, and no discontinuations due to adverse events. Early results showed an impressive ORR of 83% in heavily pretreated patients treated at active doses (50 µg/kg and above). Read the full release: https://bit.ly/3OKDn1v #ASH24

Join Dr. Robert H. Christenson and Dr. Phillip D. Levy as they explore the groundbreaking potential of high sensitivity diagnostic immunoassay testing in our live webinar on Wednesday, September 18th at 1:00 PM ET / 12:00 PM CT / 10:00 AM PT, hosted by Medical Laboratory Observer. Learn more about how these advancements are shaping the future of cardiac care and beyond! Register Today ➡ https://lnkd.in/dWUfyA9r #DiagnosticTesting #Immunoassay #CardiacCare #ClinicalDiagnostics #PrecisionMedicine

Join Dr. Robert H. Christenson and Dr. Phillip D. Levy as they explore the groundbreaking potential of high sensitivity diagnostic immunoassay testing in our live webinar on Wednesday, September 18th at 1:00 PM ET / 12:00 PM CT / 10:00 AM PT, hosted by Medical Laboratory Observer.   Learn more about how these advancements are shaping the future of cardiac care and beyond! Register Today ➡ https://lnkd.in/dWUfyA9r #DiagnosticTesting #Immunoassay #CardiacCare #ClinicalDiagnostics #PrecisionMedicine

💡 Feature Article 💡 Spectral Medical Inc. (TSX:EDT) is seeking to improve outcomes for millions of patients with life-threatening endotoxic septic shock (ESS), by combining its targeted diagnostic, Endotoxin Activity Assay (EAA), with its therapeutic hemoperfusion device, Toraymyxin (PMX), to identify and remove endotoxin from the bloodstream. In our latest #BioTuesdays feature article, Chris Seto discusses how this dual approach tackles the root cause of ESS, providing new hope for millions affected worldwide. 🔗 https://lnkd.in/gEzWSrAy Kilmer Lucas Inc.

Today is World Thrombosis Day, observed on 13th October to mark the birthday of Rudolf Virchow, a German pioneer of the pathophysiology of thrombosis. Thrombosis, commonly known as blood clots within vessels, contributes to 1 in 4 deaths worldwide and is a leading cause of cardiovascular death. This year’s theme urges everyone to Move Against Thrombosis, and raise awareness of risk factors, signs and symptoms. To learn more and support World Thrombosis Day, visit www.worldthrombosisday.org. Quadratech Diagnostics Ltd are committed to offering an extensive portfolio of diagnostic reagents for investigating coagulation pathways, haemophilia, thrombophilia, fibrinolysis and platelet function, alongside diagnostic tests for antithrombotic drug monitoring and thrombodynamics. To learn more, visit: https://lnkd.in/g9FsZhvr. #WTDay24 #worldthrombosisday #quadratechdiagnostics #ISTH #medicaldiagnostics #medicalsupplies #research

Did you know that Worldwide partners with over 115 rare disease organizations around the globe to help leverage shared expertise so we can improve patient outcomes and accelerate breakthroughs in drug development? Learn more about these partnerships and how these organizations are helping make an impact on rare disease clinical research in our blog: https://bit.ly/3V5djBD

Here’s a simulation of my own beating heart, developed by ELEM Biotech. ❤️ As the World Heart Federation highlights, cardiovascular disease (CVD) is the leading cause of deaths worldwide, with more than 20.5 million every year. Replicating the complex environment of CVD for drug testing is a major challenge due to its heterogeneity and its progressive nature, which makes it difficult to predict long-term responses based on short-term trial data. ELEM Biotech’s #VirtualHearts provide virtual patient populations for in-silico drug testing tailored to each particular testing scenario, enabling Pharma companies to develop SMART trials that account for a necessary population variability, accelerating the drug development. #CardiovascularHealth #UseHeart #VirtualHumanTwins #SMARTtrials #UseVirtualHearts